STOCK TITAN
  1. Home
  2. News
  3. BFRI

Biofrontera Inc - BFRI STOCK NEWS

Welcome to our dedicated news page for Biofrontera (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biofrontera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biofrontera's position in the market.

News
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
Rhea-AI Summary
Biofrontera, Inc. (BFRI) announces details for its 2024 Annual Meeting of Stockholders, including the record date and deadlines for stockholder proposals. The meeting will be held on June 12, 2024, with April 22, 2024, as the record date. Stockholders have until April 19, 2024, to submit proposals for inclusion in the proxy statement and until April 5, 2024, for proposals not included in the proxy materials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
none
-
News
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Biofrontera, Inc. (BFRI) reported record total revenues of $34.1M for 2023, a 19% increase from 2022. Operating expenses rose to $56.7M with one-time legal expenses. The company achieved a 4% revenue increase in Q4 2023 and restructured to decrease operating expenses by 8%. Strategic initiatives include sNDA submission, Phase 3 clinical studies, FDA approval for an improved formulation, and R&D for a new therapy lamp. The CEO highlighted strong sales growth and partnerships in 2023, with plans for cost management and efficiency improvements in 2024. The CFO emphasized revenue growth, balance sheet improvements, and cost optimization. Q4 2023 saw $10.6M in revenues, a $0.5M increase, and net income improved to $3.5M. Adjusted EBITDA for Q4 2023 was negative $3.2M, showing improved performance. Full-year 2023 revenues were $34.1M, operating expenses were $56.7M, and net income improved significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.71%
Tags
earnings
-
News
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Biofrontera, Inc. (BFRI) reports record revenues of $34.1M for 2023, a 19% increase from 2022. Operating expenses were $56.7M, with a 4% revenue increase in Q4 2023. The company restructured to align with business needs, initiated a strategic account strategy, and submitted sNDA for Ameluz®. Positive feedback from FDA, new R&D agreements, and Phase 3 clinical studies were highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.71%
Tags
earnings
News
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
Rhea-AI Summary
Biofrontera Inc. (BFRI) will report financial results for the three and 12 months ended December 31, 2023, on March 15, 2024. The company will host a conference call on March 18 to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
conferences earnings
-
News
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Rhea-AI Summary
Biofrontera Inc. (BFRI) closed an $8.0 million financing deal, with an additional $8.0 million tied to milestones, totaling $16 million. The funding allows the company to assume R&D activities and support commercial growth. The financing includes shares of Series B-1 Convertible Preferred Stock and warrants for Series B-3 Convertible Preferred Stock, with conversion prices and exercise conditions specified. The company received $8.0 million upfront and expects an additional $8.0 million upon meeting criteria associated with the warrants. Roth Capital Partners facilitated the private placement. The funds will be used for general business operations and to expedite the development of additional indications for Ameluz, Biofrontera's lead product approved for treating actinic keratosis. The securities issued are under a private placement and not registered under the Securities Act of 1933, requiring a resale registration statement to be filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.54%
Tags
none
-
News
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
Rhea-AI Summary
Biofrontera Inc. announces a significant reduction in the transfer price of Ameluz ® from 50% to 25% for purchases in 2024 and 2025, with step-wise increases to 35% from 2026 to 2032 for specific sales. The Company will take control of all US clinical trials of Ameluz ® from June 1, aiming for better cost management and increased revenue. The renegotiated terms, along with capital commitment, could lead to profitability by 2025, supported by potential label changes for Ameluz.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.33%
Tags
none
News
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules
Rhea-AI Summary
Biofrontera Inc. secures $8.0 million financing with potential $8.0 million second tranche tied to milestones, totaling $16 million. The company restructures supply agreement, enabling R&D activities and commercial growth. Funding from securities purchase agreement with institutional investors led by Rosalind Advisors. Shares of Series B-1 and B-3 Convertible Preferred Stock issued at $1,000 per share, with conversion to common stock at $0.7074. Anticipated aggregate gross proceeds of $16 million if all warrants are exercised.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.33%
Tags
none
-
News
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
Rhea-AI Summary
Biofrontera Inc. (BFRI) has announced that the U.S. Food and Drug Administration (FDA) has issued a 'no filing review issues identified' letter regarding the sNDA submitted by its licensor Biofrontera Bioscience GmbH to increase the maximally approved dosage from one to three tubes of Ameluz per treatment. The FDA has set a target action date of October 4, 2024, for the sNDA, which is supported by two Phase 1 safety studies. The studies showed robust safety parameters for the simultaneous use of three tubes, with systemic and application site adverse events equivalent to those with one tube. The sNDA aims at actinic keratosis (AK) field treatment, with an estimated 13 million treatments given each year for AK in the US. If granted, this approval will lead to increased use of Ameluz in the US, making it more convenient for patients and more efficient for their dermatologists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
News
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
Rhea-AI Summary
Biofrontera Inc. (Nasdaq:BFRI) announced preliminary, unaudited revenues for the three and twelve months ended December 31, 2023, achieving a record high revenue of approximately $33.8 million to $34.3 million, up approximately 19% compared with 2022. Fourth quarter revenues are anticipated to be in the range of approximately $10.4 million to $10.9 million, an increase of approximately 5% compared with the fourth quarter of 2022. Despite a slow start in the first quarter, Biofrontera experienced strong revenue growth throughout the year, with sales increasing between 34% and 37% in the second half of the year compared to the prior year. The company attributes the very strong growth in the third quarter to a price increase and customer buy-in. While fourth quarter sales grew slightly less than expected, the company maintained a solid growth trajectory in the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
none
News
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Biofrontera Inc. (NASDAQ: BFRI) reported Q3 2023 financial results, including a 106% increase in total revenues to $8.9 million, raised $4.5 million in a direct offering, and appointed Heikki Lanckriet, Ph.D. to the Board of Directors. The company also announced positive results from a Phase 1 safety study and FDA approval for a new formulation of Ameluz. Management expects full-year 2023 revenue growth of at least 25% compared with 2022 and anticipates becoming cash flow positive within approximately one and a half years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
earnings
Stock BFRI logo
Biofrontera Inc

Nasdaq:BFRI

BFRI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BFRI Stock Data

9.26M
2.00M
28.19%
39.15%
0.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Woburn

About BFRI

biofrontera pharma gmbh is a pharmaceuticals company based out of 104 waldhofer straße, heidelberg, bw, germany.